OcuSciences, Inc

Rapid, non-invasive, quantitative diagnostic for eye diseases such as diabetic retinopathy, glaucoma or AMD which guides therapy for primary eye care.

  • Stage $500K in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Ann Arbor Charter Township, MI, USA
  • Currency USD
  • Founded August 2006
  • Employees 5
  • Incorporation Type C-corp
  • Website OcuSciences.com

Company Summary

OcuSciences, Inc. is a revenue-stage, medical diagnostic device company commercializing a rapid, non-invasive test for early detection of retinal disease. OcuSciences has developed a proprietary, ocular imaging technique, Retinal Metabolic Analysis™, as a biomarker for measuring the damage to retinal tissue due to diabetes, macular degeneration, and glaucoma. Primary eye care uses the camera to detect disease and guide therapy.

Team

  • Kurt RIegger
    President & COO

    Riegger is serial entrepreneur, founder and CEO/COO of 4 venture backed companies. Riegger has 25 years of executive management experience. Leads business development, strategy and fundraising.

  • Victor Elner
    Chief Medical Officer

    Dr. Victor Elner, PhD, M.D., Ravitz Foundation Professor of Ophthalmology & Visual Sciences and Professor of Pathology at the University of Michigan Kellogg Eye Center is a co-founder of the company, creator of the method, and manages clinical trial design and contract research programs. Dr Elner is a frequent speaker at conferences on AMD and the pathology of disease

  • John Moore
    Board Advisor

    Moore is the former CEO of 4 advanced technology ophthalmic instrument companies including the first OCT instrument. Moore is on the board of OptoVue and Starr Medical. Previously Moore was VP-Alcon and president of division Zeiss Meditec.

  • Erich Heise
    Director - Business Development

    MS - Case Western Reserve University - Entrepreneurial Biotechnology
    BS - University of Michigan - Neuroscience
    Previously first employee and Business Development at Cleveland Clinic spinout, OptoQuest.
    Currently Associate Director, Business Development at Cleveland Clinic spinout, Cleveland Diagnostics.
    Director of Business Development at OcuSciences (2015 - present).

  • Collin Rich
    Chief Technology Officer

    Dr. Rich was previously a founder of Accuri Cytometers, which was later acquired by Becton Dickinson in one of the largest acquisitions in the history of Ann Arbor.

Advisors

  • Tim Damschroeder, Bodman
    Lawyer
    Unconfirmed
    Jeff Dolowy, Plante Moran
    Accountant
    Unconfirmed

Previous Investors

  • Angels
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free